Exogenous Surfactant Therapy: An Update

Levitzky MG . Pulmonary physiology, 4th ed. New York: McGraw-Hill Inc, 1995.

Enhorning G , Duffy LC , Welliver RC . Pulmonary surfactant maintains patency of conducting airways in the rat. Am J Respir Crit Care Med 1995;151(2, Part 1):554–556.

Notter RH , Morrow PE . Pulmonary surfactant: a surface chemistry viewpoint. Ann Biomed Eng 1975;3(2):119–159.

King RJ . Pulmonary surfactant. J Appl Physiol 1982;53(1):1–8.

Clements JA , Tierney DF . Alveolar instability associated with altered surface tension. In: Fenn WO , Rahn H , editors. Handbook of physiology, Section 3: respiration. Washington, DC: American Physiological Society, 1965;2:1565–1583.

Rooney SA . The surfactant system and lung phospholipid biochemistry. Am Rev Respir Dis 1985;131(3):439–460.

Burkhardt R , van Golde LMG . Lipids and lipid metabolism in the lung: basic aspects and alterations in disease states. In: Massaro D , editor. Lung cell biology. New York: Marcel Dekker Inc, 1989;41:591–654.

King RJ , Clements JA . Surface active materials from dog lung. II. Composition and physiological correlations. Am J Physiol 1972;223(3):715–726.

Hawgood S , Benson BJ . The molecular biology of surfactant apopro-teins. In: Massaro D , editor. Lung cell biology. New York: Marcel Dekker Inc, 1989;41:701–734.

Voelker DR , Mason RJ . Alveolar type II epithelial cells. In: Massaro D , editor. Lung cell biology. New York: Marcel Dekker Inc, 1989;41:487–538.

Possmayer F. The role of surfactant-associated proteins (editorial). Am Rev Respir Dis 1990;142(4):749–752.

Lewis JF , Jobe AH . Surfactant and the adult respiratory distress syn-drome. Am Rev Respir Dis 1993;147(1):218–233. See the published erratum Am Rev Respir Dis 1993;147(4):1068.

Sueishi K , Benson BJ . Isolation of a major apolipoprotein of canine and murine pulmonary surfactant biochemical and immunochem-ical characteristics. Biochim Biophys Acta 1981;665(3):442–453.

Holm BA , Matalon S. Role of pulmonary surfactant in the development and treatment of adult respiratory distress syndrome. Anesth Analg 1989;69(6):805–818.

Yukitake K , Brown CL , Schlueter MA , Clements JA , Hawgood S. Surfactant apoprotein A modifies the inhibitory effect of plasma proteins on surfactant activity in vivo. Pediatr Res 1995;37(1):21–25.

Persson A , Chang D , Rust K , Moxley M , Longmore W , Crouch E. Purification and biochemical characterization of CP4 (SP-D), a col-lagenous surfactant-associated protein. Biochem 1989;28(15):6361–6367.

Goerke J. Lung surfactant. Biochim Biophys Acta 1974;344(3-4):241–261.

Jobe A. Metabolism of endogenous surfactant and exogenous surfactants for replacement therapy. Semin Perinatol 1988;12(3):231–244.

Wright JR , Clements JA . Lung surfactant turnovers and factors that affect turnover. In: Massaro D , editor. Lung cell biology. New York: Marcel Dekker Inc, 1989;41:655–699.

Goerke J , Clements JA . Alveolar surface tension and lung surfac-tant. In: Fishman AP , editor. Handbook of physiology, Section 3: the respiratory system. Bethesda, MD: American Physiological Society, 1986;3:247–261.

Young SL , Silbajoris RA . Type II cell response to chronic beta adren-ergic agonist and antagonist infusions. J Pharmacol Exp Ther 1985;233(1):271–276.

Avery ME , Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959;97:517–523.

Ashbaugh DG , Bigelow DB , Petty TL , Levine BE . Acute respira-tory distress in adults. Lancet 1967;2(7511):319–323.

Petty TL , Ashbaugh DG . The adult respiratory distress syndrome. Clinical features, factors influencing prognosis, and principles of man-agement. Chest 1971;60(3):233–239.

Repine JE . Scientific perspectives on adult respiratory distress syn-drome. Lancet 1992;339(8791):466–469.

Demling RH . Adult respiratory distress syndrome: current concepts. New Horiz 1993;1(3):388–401.

Bernard GR , Artigas A , Brigham KL , Carlet J , Falke K , Hudson L , et al. The American-European con-sensus conference on ARDS: definitions, mechanisms, relevant out-comes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149(3, Part 1):818–824.

Seeger W , Günther A. Surfactant and adult respiratory distress syn-drome. In: Müller B , von Wichert P , editors. Lung surfactant: basic research in the pathogenesis of lung disorders. Prog Respir Res 1994;27:222–231.

Hallman M , Maasilta P , Sipilä I , Tahvanainen T. Composition and function of pulmonary surfactant in adult respiratory distress syn-drome. Eur Respir J Suppl 1989;2(3, Suppl):104S–108S.

Hallman M , Spragg R , Harrell JH , Moser KM , Gluck L. Evidence of lung surfactant abnormality in respiratory failure. Study of bron-choalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982;70(3):673–683.

Pison U , Seeger W , Buchhorn R , Joka T , Brand M , Obertacke U , et al. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis 1989;140(4):1033–1039.

Gregory TJ , Longmore WJ , Moxley MA , Whitsett JA , Reed CR , Fowler AA III , et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991;88(6):1976–1981.

Hall SB , Notter RH , Smith RJ , Hyde RW . Altered function of pul-monary surfactant in fatty acid lung injury. J Appl Physiol 1990;69(3):1143–1149.

Lewis JF , Ikegami M , Jobe AH . Altered surfactant function and metabolism in rabbits with acute lung injury. J Appl Physiol 1990;69(6):2303–2310.

Berry D , Ikegami M , Jobe A. Respiratory distress and surfactant inhi-bition following vagotomy in rabbits. J Appl Physiol 1986;61(5):1741–1748.

Pison U , Obertacke U , Seeger W , Hawgood S. Surfactant protein A (SP-A) is decreased in acute parenchymal lung injury associated with polytrauma. Eur J Clin Investig 1992;22(11):712–718.

Higuchi R , Lewis J , Ikegami M. In vitro conversion of surfactant sub-types is altered in alveolar surfactant isolated from injured lungs. Am Rev Respir Dis 1992;145(6):1416–1420.

Veldhuizen RAW , McCaig L , Akino T , Lewis JF . Alveolar surfactant aggregates are altered in patients with adult respiratory distress syn-drome (abstract). Am J Respir Crit Care Med 1994;149(4):A124.

Lachmann B , Hallman M , Bergmann KC . Respiratory failure fol-lowing anti-lung serum: study on mechanisms associated with sur-factant system damage. Exp Lung Res 1987;12(2):163–180.

Kobayashi T , Nitta K , Ganzuka M , Inui S , Grossman G , Robertson B. Inactivation of exogenous surfactant by pulmonary edema fluid. Pediatr Res 1991;29(4, Part 1):353–356.

Jobe A , Ikegami M , Jacobs H , Jones S , Conaway D. Permeability of premature lamb lungs to protein and the effect of surfactant on that permeability. J Appl Physiol 1983;55(1, Part 1):169–176.

Hallman M , Merritt TA , Bry K. The fate of exogenous surfactant in neonates with respiratory distress syndrome. Clin Pharmacokinet 1994;26(3):215–232.

Ten Centre Study Group. Ten centre trial of artificial surfactant (arti-ficial lung expanding compound) in very premature babies. Br Med J Clin Res Ed 1987;294(6578):991–996.

Morley CJ , Greenough A , Miller NG , Bangham AD , Pool J , Wood S , et al. Randomized trial of artificial surfactant (ALEC) given at birth to babies from 23 to 34 weeks gestation. Early Hum Dev 1988;17(1):41–54.

Morley CJ , Morley R. Follow up of premature babies treated with artificial surfactant (ALEC). Arch Dis Child 1990;65(7, Special Num-ber):667–669.

Macnaughton PD , Evans TW . The effect of exogenous surfactant therapy on lung function following cardiopulmonary bypass. Chest 1994;105(2):421–425.

Abbasi S , Bhutani VK , Gerdes JS . Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exoge-nous surfactant. J Pediatr 1993;122(3):446–452.

Bose C , Corbet A , Bose G , Garcia-Prats J , Lombardy L , Wold D , et al. Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant. J Pedi-atr 1990;117(6):947–953.

Corbet A , Gerdes J , Long W , Avila E , Puri A , Rosenberg A , Edwards K , Cook L , and the American Exosurf Neonatal Study Groups I and IIa. Double-blind, randomized trial of one versus three prophylac-tic doses of synthetic surfactant in 826 neonates weighing 700-1100 grams: effects on mortality rate. J Pediatr 1995;126(6):969–978.

Corbet A , Long W , Schumacher R , Gerdes J , Cotton R. Double-blind developmental evaluation at 1-year corrected age of 597 premature infants with birth weights from 500 to 1350 grams enrolled in three placebo-controlled trials of prophylactic synthetic surfactant. American Exo-surf Neonatal Study Group I. J Pediatr 1995;126(5, Part 2):S5–12.

Corbet A , Bucciarelli R , Goldman S , Mammel M , Wold D , Long W , and the American Exosurf Pediatric Study Group. Decreased mor-tality rate among small premature infants treated at birth with a sin-gle dose of synthetic surfactant: a multicenter controlled trial. J Pedi-atr 1991;118(2):277–284.

Horbar JD , Wright LL , Soll RF , Wright EC , Fanaroff AA , Korones SB , et al, and the National Institute of Child Health and Human Devel-opment Neonatal Research Network. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr 1993;123(5):757–766.

Long W , Thompson T , Sundell H , Schumacher R , Volberg F , Guthrie R , and the American Exosurf Neonatal Study Group I. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome. J Pediatr 1991;118(4, Part 1):595–605.

Kraybill EN , Bose CL , Corbett AJ , Garcia-Prats J , Asbill D , Edwards K , Long W. Double-blind evaluation of developmental and health status to age 2 years of infants weighing 700 to 1350 grams treated prophylactically at birth with a single dose of synthetic surfactant or air placebo. J Pediatr 1995;126(5, Part 2):S33–42.

Sell M , Cotton R , Hirata T , Guthrie R , LeBlanc M , Mammel M , Long W , and the American Exosurf Neonatal Group I. One-year follow up of 273 infants with birth weights of 700 to 1100 grams after pro-phylactic treatment of respiratory distress syndrome with synthetic surfactant or air placebo. J Pediatr 1995;126(5, Part 2):S20–25.

Wiedemann H , Baughman R , DeBoisblanc E , Shuster D , Caldwell E , Weg J , et al, and the Exosurf ARDS Sepsis Study Group. A mul-ticenter trial in human sepsis-induced ARDS of an aerosolized syn-thetic surfactant (Exosurf) (abstract). Am Rev Respir Dis 1992;145:A184.

Weg JG , Balk BA , Tharratt S , Jenkins SG , Shah JB , Zaccardelli D , et al. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA 1994;272(18):1433–1438.

Wach R , Darlow B , Bourchier D , Broadbent R , Knight D , Selby R. Respiratory distress syndrome in New Zealand: evidence from the OSIRIS trial of exogenous surfactant (Exosurf). N Z. Med J 1994;107(980):234–237.

The OSIRIS Collaborative Group. Early versus delayed neonatal administration of a synthetic surfactant-the judgment of OSIRIS. Lancet 1992;340(8832):1363–1369.

Sweeney TD , Reinisch US , Kirk JE , Vitow C , Offord S , Glavinos P , Ingenito E , Brain JD . A synthetic phospholipid- KL4 surfactant improves lung function in a rat model of ARDS (abstract). Am J Respir Crit Care Med 1994;149(4):A126.

Zola EM , Overbach AM , Gunkel JH , Mitchell BR , Nagle BT , DeMarco NG , et al. Treatment investigational new drug experience with Survanta (beractant). Pediatrics 1993;91(3):546–551.

Lotze A , Knight GR , Martin GR , Bulas DI , Hull WM , O'Donnell RM , et al. Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J Pediatr 1993;122(2):261–268.

Gregory TG , Longmore WJ , Moxley MA , Cai G-Z , Gadek JE , Wei-land JE , et al. Surfactant repletion following Survanta supplemen-tation in patients with acute respiratory distress syndrome (ARDS) (abstract). Am J Respir Crit Care Med 1994;149:A124.

Ferrara TB , Hoekstra RE , Couser RJ , Gaziano EP , Calvin SE , Payne NR , Fangman JJ . Survival and follow up of infants born at 23 to 26 weeks gestational age: effects of surfactant therapy. J Pediatr 1994;124(1):119–124.

Jobe AE . Pulmonary surfactant therapy. N Engl J Med 1993;328(12):861–868.

Lachmann B. Animal models and clinical pilot studies of surfactant replacement in adult respiratory distress syndrome. Eur Respir J Suppl 1989;2(3):98s–103s.

Harris JD , Jackson F Jr , Moxley MA , Longmore WJ . Effect of exoge-nous surfactant instillation on experimental acute lung injury. J Appl Physiol 1989;66(4):1846–1851.

Lewis JF , Ikegami M , Jobe AH . Metabolism of exogenously admin-istered surfactant in the acutely injured lungs of adult rabbits. Am Rev Respir Dis 1992;145(1):19–23.

Hall SB , Lu RZ , Venkitaraman AR , Hyde RW , Notter RH . Inhib-ition of pulmonary surfactant by oleic acid mechanisms and char-acteristics. J Appl Physiol 1992;72(5):1708–1716.

Schuster DP . ARDS: clinical lessons from the oleic acid model of acute lung injury. Am J Respir Crit Care Med 1994;149(1):245–260.

Kaneko T , Sato T , Katsuya H , Miyauchi Y. Surfactant therapy for pulmonary edema due to intratracheally injected bile acid. Crit Care Med 1990;18(1):77–83.

Eijking EP , Gommers D , So KL , Vergeer M , Lachmann B. Surfactant treatment of respiratory failure induced by hydrochloric acid aspi-ration in rats. Anesthesiology 1993;78(6):1145–1151.

Fracica PJ , Caminiti SP , Piantadosi CA , Duhaylongsod FG , Crapo JD . Young SL . Natural surfactant and hyperoxic lung injury in primates. II. Morphometric analyses. J Appl Physiol 1994;76(3):1002–1010.

Huang YC , Caminiti SP , Fawcett TA , Moon RE , Fracica PJ , Miller FJ , et al. Natural surfactant and hyperoxic lung injury in primates I. Physiology and biochemistry. J Appl Physiol 1994;76(3):991–1001.

Novotny WE , Hudak BH , Matalon S , Holm BA . Hyperoxic lung injury reduces exogenous surfactant clearance in vivo. Am J Respir Crit Care Med 1993;151:1843–1847.

van't Veen A , So KL , Lachmann B. Surfactant replacement therapy in animal models of respiratory failure due to viral infection. In: Vaupel P , editor. Oxygen transport to tissue. New York: Plenum Press, 1994;15:83–94.

Matalon S , Holm BA , Notter RH . Mitigation of pulmonary hyper-oxic injury by administration of exogenous surfactant. J Appl Phys-iol 1987;62(2):756–761.

Sachs S , Ghio AJ , Young SL , Piantados CA . Mechanism of protection against hyperoxic lung injury by components of artificial surfactant (abstract). Am J Respir Crit Care Med 1994;149(4 Part 2):A450.

Ikegami M , Ueda T , Absolom D , Baxter C , Rider E , Jobe AH . Changes in exogenous surfactant in ventilated preterm lamb lungs. Am Rev Respir Dis 1993;148(4, Part 1):837–844.

Thomassen MJ , Antal JM , Conners MJ , Meeker DP , Weidemann HP . Characterizations of Exosurf (surfactant)-mediated suppression of stimulated human alveolar macrophage cytokine responses. Am J Respir Cell Mol Bio 1994;10(4):399–404.

Allen JN , Moore SA , Pope-Harman AL , Marsh CB , Wewers MD . Immunosuppressive properties of surfactant and plasma on alveo-lar macrophages. J Lab Clin Med 1995;125(3):356–369.

Roth MD , Pinto M , Golub SH , Shau H. Pulmonary surfactant inhibits interleukin-2-induced proliferation and the generation of lymphokine-activated killer cells. Am J Respir Cell Mol Bio 1993;9(6):652–658.

Thomassen MJ , Meeker DP , Antel JM , Conners MJ , Wiedemann HP . Synthetic surfactant (Exosurf) inhibits endotoxin-stimulated cytokine secretion by human alveolar macrophages. Am J Respir Cell Mol Biol 1992;7(3):257–260.

Cummings JJ , Holm BA , Hudak ML , Hudak BB , Ferguson WH , Egan EA . A controlled clinical comparison of four different surfactant prepa-rations in surfactant-deficient preterm lambs. Am Rev Respir Dis 1992;145(5):999–1004.

Hall SB , Venkitaraman AR , Whitsett JA , Holm BA , Notter RH . Impor-tance of hydrophobic apoproteins as constituents of clinical exoge-nous surfactants. Am Rev Respir Dis 1992;145(1):24–30.

Fujiwara T , Maeta H , Chida S , Morita T , Watabe Y , Abe T. Arti-ficial surfactant therapy in hyaline membrane disease. Lancet 1980;1(8159):55–59.

Raju TN , Langenberg P. Pulmonary hemorrhage and exogenous sur-factant therapy: a meta-analysis. J Pediatr 1993;123(4):603–610.

Hennes HM , Lee MB , Rimm AA , Shapiro DL . Surfactant replace-ment therapy in respiratory distress syndrome. Meta-analysis of clin-ical trials of single-dose surfactant extracts. Am J Dis Child 1991;145:102–104.

American Association for Respiratory Care Perinatal-Pediatrics Guide-lines Committee. Surfactant replacement therapy. Respir Care 1994;39(8):824–829.

Gortner L , Bartmann P , Pohlandt F , Bernsau U , Porz F , Hellwege HH , et al. Early treatment of respiratory distress syndrome with bovine surfactant in very preterm infants: a multicenter controlled clinical trial. Pediatr Pulmonol 1992;14(1):4–9.

Kendig JW , Notter RH , Cox C , Aschner JL , Benn S , Bernstein RM , et al. Surfactant replacement therapy at birth: final analysis of a clin-ical trial and comparisons with similar trials. Pediatrics 1988;82(5):756–762.

Halliday HL , Tarnow-Mordi WO , Corcoran JD , Patterson CC . Mul-ticentre randomized trial comparing high and low dose surfactant reg-imens for the treatment of respiratory distress syndrome (the Curo-surf 4 trial). Arch Dis Child 1993;69(3, Special Number):276–280.

Merritt TA , Halliday HL . On exogenous surfactant therapy (edito-rial). Pediatr Pulmonol 1992;14(1):1–3. See the published erratum in Pediatr Pulmonol 1992;14(1):10–15.

Long W , Zucker J , Kraybill E. Symposium on synthetic surfactant. II: perspective and commentary. J Pediatr 1995;126(5, Part 2):S1–S5.

Walther FJ , Mullett M , Schumacher R , Sundell H , Easa D , Long W , and the American Exosurf Neonatal Study Group. One-year follow up of 66 premature infants weighing 500 to 699 grams treated with a single dose of synthetic surfactant or air placebo at birth: results of a double-blind trial. J Pediatr 1995;126(5, Part 2):S13–19.

Richman PS , Spragg RG , Robertson B , Merritt TA , Curstedt T. The adult respiratory distress syndrome: first trials with surfactant replace-ment. Eur Respir J Suppl 1989;2(3):109s–111s.

Nosaka S , Sakai T , Yonekura M , Yoshikawa K. Surfactant for adults with respiratory failure (letter). Lancet 1990;336(8720):947–948.

Heikinheimo M , Hynynen M , Rautiainen P , Andersson S , Hallman M , Kukkonen S. Successful treatment of ARDS with two doses of synthetic surfactant. Chest 1994;105(4):1263–1264.

Weg JG , Reines H , Balk R , Tharratt S , Kearney P , Killian T , et al, and the Exosurf-ARDS Sepsis Study Group. Safety and efficacy of an aerosolized surfactant (Exosurf) in human sepsis-induced ARDS (abstract). Chest 1991;100(2):137S.

Anzueto A , Baughman R , Guntupalli K , DeMaria E , Davis K , Weg J , et al, and the Exosurf ARDS Sepsis Study Group. An international, randomized, placebo-controlled trial evaluating the safety and effi-cacy of aerosolized surfactant in patients with sepsis-induced ARDS (abstract). Am J Respir Crit Care Med 1994;149(4, Part 2):A567. Also see Anzueto A , Baughman RP , Guntupalli KK , Weg JG , Wiedemann HP , Raventós AA , et al. Aerosolized surfactant in sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996; (in press).

Gregory TJ , Longmore WJ , Moxley MA , Cai G-Z , Gadek JE , Wei-land JE , et al. Surfactant repletion following Survanta supplemen-tation in patients with acute respiratory distress syndrome (ARDS) (abstract). Am J Respir Crit Care Med 1994;149:A124.

Spragg RG , Gilliard N , Richman P , Smith RM , Hite RD , Pappert D , et al. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest 1994;105(1):195–202.

Jobe A , Ikegami M. Surfactant for the treatment of respiratory dis-tress syndrome. Am Rev Respir Dis 1987;136(5):1256–1275.

Jobe A , Ikegami M , Jacobs H , Jones S. Surfactant and pulmonary blood flow distributions following treatment of premature lambs with natural surfactant. J Clin Invest 1984;73(3):848–856.

Gilliard N , Richman PM , Merritt TA , Spragg RG . Effect of volume and dose on the pulmonary distribution of exogenous surfactant admin-istration to normal rabbits or to rabbits with oleic acid lung injury. Am Rev Respir Dis 1990;141(3):743–747.

Van der Bleek J , Plotz FB , Van Overbeek FM , Heikamp A , Beekhuis H , Wildevuur RH , et al. Distribution of exogenous surfactant in rab-bits with severe respiratory failure: the effect of volume. Pediatr Res 1993;34(2):154–158.

O'Brodovich H , Hannam V. Exogenous surfactant rapidly increases Pao₂ in mature rabbits with lungs that contain large amounts of saline. Am Rev Respir Dis 1993;147(5):1087–1090.

Lewis JF , Ikegami M , Jobe AH , Tabor B. Aerosolized surfactant treat-ment of preterm lambs. J Appl Physiol 1991;70(2):869–876.

Lewis J , Ikegami M , Higuchi R , Jobe A , Absolom D. Nebulized vs instilled exogenous surfactant in an adult lung injury model. J Appl Physiol 1991;71(4):1270–1276.

Lewis JF , Ikegami M , Jobe AH , Absolom D. Physiologic responses and distribution of aerosolized surfactant (Survanta) in a nonuni-form pattern of lung injury. Am Rev Respir Dis 1993;147(6, Part 1):1364–1370.

Lewis JF , McCaig L. Aerosolized versus instilled exogenous sur-factant to a nonuniform pattern of lung injury. Am Rev Respir Dis 1993;148(5):1187–1193.

Raabe OG , Lee JIC , Wong GA . A signal actuated nebulizer for the use with breathing machines. J Aerosol Med 1989;2:201–210.

Haas CF , Weg JG , Kettell CW , Caldwell EJ , Zaccardelli DS , Brown DL . Effects of dense, high-volume, artificial surfactant aerosol on a heated exhalation filter system. Crit Care Med 1993;21(1):125–130.

Haas CF , Folk LM , Weg JG , Zaccardelli DS , Brown DL . A nebu-lizer system for administering synthetic surfactant (abstract). Respir Care 1992;37(11):1367.

Coleman RE , MacIntyre N , Snyder G , Pattishall E , Zaccardelli D. Aerosol characteristics of Tc-Pentetic acid (DTPA) and synthetic surfactant (Exosurf). Chest 1994;105(6):1765–1769.

Haas CF , Johnson SJ , Weg JG , Zaccardelli DS , Pattishall EN . A devel-opmental exhalation aerosol filter for synthetic surfactant during mechanical ventilation (abstract). Respir Care 1992;37(11):1367.

Haas CF , Weg JG , Zaccardelli DS . Effect of changing compliance, expiratory resistance, and inspiratory flow pattern with the Visan-9 nebulizer (abstract). Respir Care 1993;38(11):1293.

Haas CF , Folk LM , Weg JG , Zaccardelli DS . PEFR as an early indi-cator of filter occlusion due to surfactant aerosol therapy (abstract). Respir Care 1991;36(11):1279–1280.

MacIntrye NR , Coleman RE , Schuller FS , Zaccardelli D , Pattishall E. Efficiency of the delivery of aerosolized artificial surfactant to intu-bated patients with adult respiratory distress syndrome (abstract). Am J Respir Crit Care Med 1994;149(4, Part 2):A125.

Shinwell ES , Robertson B , Saugstad OD , Halliday HL , Speer CP . Update on surfactant therapy. Biol Neonate 1995;67(1):2–12.